Adagene (ADAG) vs Whitehawk Therapeutics (WHWK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Whitehawk Therapeutics (WHWK) has outperformed Adagene (ADAG) over the past year, gaining 62.9% versus a gain of 42.2%. Over five years, ADAG leads with a -76.2% price change compared with -87.2% for WHWK. Whitehawk Therapeutics is the larger company by market cap ($197.5 million vs $179.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADAG | WHWK |
|---|---|---|
| Share price | $2.67 | $3.47 |
| Market cap | $179.27M | $197.54M |
| 1-day change | -3.96% | -0.14% |
| YTD return | +47.09% | +43.39% |
| 1-year return | +42.20% | +62.91% |
| 5-year return | -76.24% | -87.25% |
| EPS (TTM) | $-0.37 | $-1.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.85 | $5.50 |
| 52-week low | $1.30 | $1.87 |
| Distance from 52-week high | -44.95% | -36.94% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +271.16% | +122.51% |
| Average volume | 244.76K | 367.72K |
| Shares outstanding | 67.14M | 57.01M |
| Employees | 128 | 32 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- WHWK has outperformed ADAG by 20.7 percentage points over the past year.
About Adagene
ADAG stock →Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About Whitehawk Therapeutics
WHWK stock →Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 32 employees
ADAG vs WHWK FAQ
Which is bigger, Adagene or Whitehawk Therapeutics?
Whitehawk Therapeutics (WHWK) is larger, with a market capitalization of $197.54M compared with $179.27M for Adagene (ADAG).
Which stock has performed better over the past year, ADAG or WHWK?
WHWK returned +62.91% over the past 12 months, compared with +42.20% for ADAG (price return, excluding dividends). Past performance does not predict future results.
Are Adagene and Whitehawk Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.